These press releases are for business and financial media.
-
-
- Press release archive 2008
- 31 January 2008
- Fourth Quarter and Full Year Results 2007
-
-
-
- Press release archive 2008
- 21 January 2008
- AstraZeneca Becomes Major Sponsor of Shanghai Expo UK Pavilion AstraZeneca China has agreed to become a major sponsor of the UK Pavilion at Shanghai Expo 2010. AstraZeneca’s sponsorship will amount to £500,000 and will directly support the design, development and staging of the British pavilion.
-
-
-
- Press release archive 2008
- 15 January 2008
- First Head to Head Study Comparing CRESTOR™ and LIPITOR® Effects on the Treatment of Atherosclerosis AstraZeneca today announced the launch of a new clinical trial, SATURN, designed to measure the impact of CRESTOR™ (rosuvastatin) 40 mg and atorvastatin (Lipitor®) 80 mg on the progression of atherosclerosis in high risk patients. SATURN will compare the effects of these two statins on the ability to decrease progression or induce regression of atherosclerosis, the main cause of cardiovascular disease, following two years of treatment in patients with coronary artery disease.
-
-
-
- Press release archive 2008
- 02 January 2008
- AstraZeneca Submits sNDAs for Seroquel XR™ for the Treatment of Bipolar Mania and Bipolar Depression AstraZeneca today announced that the company has submitted two separate supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) for once-daily SEROQUEL XR™ (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder.
-
-
-
- Press release archive 2007
- 14 December 2007
- ARIMIDEX Significantly Superior to Tamoxifen in Reducing Risk Of Breast Cancer Returning and Increasing Disease-Free Survival Landmark results from one of the world’s largest breast cancer trials, presented today at the San Antonio Breast Cancer Symposium (SABCS) USA, and published online in The Lancet Oncology, reinforce that ARIMIDEX (anastrozole) is significantly superior to tamoxifen in reducing the risk of breast cancer returning and in increasing disease-free survival (DFS) in postmenopausal women with hormone receptor positive (HR+) early disease.
-
-
-
- Press release archive 2007
- 12 December 2007
- AstraZeneca Files Patent Infringement Actions in Response to Crestor™ ANDAs AstraZeneca today announced that it has filed patent infringement actions in United States District Court, District of Delaware, against seven generic drug manufacturers, which have submitted Abbreviated New Drug Applications (ANDAs) for Crestor™
-
-
-
- Press release archive 2007
- 10 December 2007
- FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM® (Esomeprazole Magnesium) The US Food and Drug Administration (FDA) today issued its final assessment of two small, open, long-term, clinical studies in patients with gastro-esophageal reflux disease (GERD), comparing anti-reflux surgery with either omeprazole (SOPRAN study) or NEXIUM ® (LOTUS study) treatment.
-
-
-
- Press release archive 2007
- 07 December 2007
- AstraZeneca Presents its Global Biologics Organisation, MedImmune, at 2007 Analyst and Investor R&D Day AstraZeneca (AZN) today holds an R&D day for analysts and investors at the headquarters of its global biologics organisation, MedImmune, in Gaithersburg, Maryland, USA, to present its recently expanded world-class biologics expertise. At the meeting, which will run from 9:00 AM to 3:00 PM EST, senior leaders from MedImmune will present the Company’s highly developed capabilities in antibody and vaccine discovery, development, production and commercialisation within the broader context of AstraZeneca’s R&D
-
-
-
- Press release archive 2007
- 29 November 2007
- AstraZeneca Receives Six Months Paediatric Exclusivity Patent Extension For ARIMIDEX® From The FDA AstraZeneca today announced that the United States (US) Food and Drug Administration (FDA) has granted an additional six month period of exclusivity to market ARIMIDEX® (anastrozole) for its licensed breast cancer indications until June 2010. Prior to paediatric exclusivity being granted by the FDA, the patent was due to expire in December 2009.
-
Not signed in
Page tools
Share price
- London
-
28.34 GBP - New York
-
43.13 USD - Stockholm
-
326.80 SEK
At 09-Feb-2010 11:36 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
